Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-8862
Authors: | Schultheis, Michael Staubach, Petra Grabbe, Stephan Ruckes, Christian Stetbut, Esther von Kirschner, Uwe Matusiak, Łukasz Szepietowski, Jacek C. Nikolakis, Georgios |
Title: | LAight® therapy is an effective treatment option to maintain long-term remission of Hurley I and II Hidradenitis Suppurativa: results from period B of RELIEVE, a multicenter randomized, controlled trial |
Online publication date: | 19-Apr-2023 |
Year of first publication: | 2022 |
Language: | english |
Abstract: | Background: Hidradenitis suppurativa is a chronic, inflammatory, burdensome skin disease where current first-line treatments are limited to topical and/or systemic antibiotics which cannot be applied for long-term disease management. Period B of the RELIEVE study analyzes whether LAight® therapy can sustain or even increase remission after a first topical antibiotic treatment cycle. Methods: The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating Hurley I and II patients were randomized to either a group receiving topical clindamycin 1% solution combined with 8 additional bi-weekly treatments with LAight® therapy (group TC + L) or a group which was treated with topical clindamycin 1% solution only (group TC). After 16 weeks, patients entered open-label period B and both groups were treated exclusively with LAight® therapy for an additional 16 weeks (8 sessions, group TC + L/L and group TC/L). Results: In total, 88 patients were enrolled in RELIEVE. Seventy-eight patients entered period B; 39 belonged to group TC + L/L and 39 to group TC/L. The IHS4-response at the start of period B was 62% (group TC + L/L) and 33% (group TC + L). During the 16 weeks of additional monotherapy with LAight, in both groups >90% of patients who responded to therapy in period A maintained their IHS4-response at week 32. IHS4 response rates continued to rise up to 79% of the TC + L/L group and up to 71% of the TC/L group during period B at week 32. Achievement of HiSCR and certain patient reported outcomes confirmed primary endpoint results. Conclusion: LAight® therapy is an effective approved therapy option for Hurley I and II HS that can be used continuously to maintain treatment success. During 16 weeks of follow-up in period B, over 90% of patients with response after period A maintained their treatment outcome, while more than 60% of prior nonresponders gained response. The fact that LAight® therapy can be applied continuously, is very effective and is well tolerated makes it a valuable treatment tool in the design of HS long- term treatment modalities. |
DDC: | 610 Medizin 610 Medical sciences |
Institution: | Johannes Gutenberg-Universität Mainz |
Department: | FB 04 Medizin |
Place: | Mainz |
ROR: | https://ror.org/023b0x485 |
DOI: | http://doi.org/10.25358/openscience-8862 |
Version: | Published version |
Publication type: | Zeitschriftenaufsatz |
Document type specification: | Scientific article |
License: | CC BY |
Information on rights of use: | https://creativecommons.org/licenses/by/4.0/ |
Journal: | Dermatology 238 6 |
Pages or article number: | 1092 1103 |
Publisher: | Karger |
Publisher place: | Basel ; Freibung [Breisgau] ; Paris ; London ; New York ; Bangalore ; Bankok ; Singapore ; Tokyo ; Sydney |
Issue date: | 2022 |
ISSN: | 1421-9832 |
Publisher DOI: | 10.1159/000524739 |
Appears in collections: | DFG-491381577-H |
Files in This Item:
File | Description | Size | Format | ||
---|---|---|---|---|---|
![]() | laight®_therapy_is_an_effecti-20230227091250479.pdf | 701.43 kB | Adobe PDF | View/Open | |
laight®_therapy_is_an_effecti-20230227091303292.pptx | 419.1 kB | Microsoft Powerpoint XML | View/Open |